Urs Spitz (Biosynth AG)

Spitz, Urs (Biosynth 201905 CEO)

	Organisation	Biosynth AG
	Group	Biosynth (since 9/22) (Group)
	Product	fine chemicals
	Product 2	reagents (bio/biochemical)

Biosynth AG. (5/20/19). "Press Release: Biosynth and Carbosynth Merge to Form a Leading Player in the Global Fine Chemicals Market". Staad & Compton.

Biosynth and Carbosynth announced their merger as a major step in consolidating their positions as leading suppliers in the constantly evolving fine chemical market, where mergers and acquisitions amongst the customer base of both companies have been a regular part of the landscape. Both companies have diverse expertise in organic synthesis and different focuses in their product portfolio of bio-chemicals. Carbosynth is a leader in carbohydrate chemistry, while Biosynth has a wealth of experience with enzyme substrates and has recently attracted much attention with a number of novel chemiluminescence-based compounds. The new company will benefit from having highly skilled employees across the globe and allow an even more rapid response time for customer enquiries and technical support.

Dr. Urs Spitz, President of Biosynth said “Since both companies have a complementary product offering and technical know-how, and have been successfully working together on joint projects, this acquisition seems like a natural progression.”

Dr. Vanessa Eastwick-Field, Managing Director of Carbosynth, added ”We are delighted to join forces and pool resources with Biosynth, who we have known and worked with for many years. They have a proven track record of looking after customers and an extensive line of biomedical products to match their expertise in manufacturing and GMP. This new partnership will enhance the relationship we have with our customers, create a more streamlined and comprehensive product range and allow for even better customer service”.

About Biosynth

Biosynth is an accomplished firm with a successful history in the field of biochemicals for the diagnostics, pharmaceutical and chemical industries as well as food and environmental analysis. With its headquarters and main production in Switzerland and sites in Slovakia, the USA and China, Biosynth offers a product base of over 100’000 substances. Biosynth is an excellent partner for both industrial scale and research customers. Development projects, GMP, small and industrial scale manufacturing, as well as global sourcing are all core competencies of the Biosynth group.

About Carbosynth

Carbosynth is a leading worldwide supplier of carbohydrates, nucleosides and biochemicals to research and development scientists in the pharmaceutical and biotechnology industries. Established in 2006 near Oxford, the company has built a global organisation with operations in the UK, USA and China. With a diverse and comprehensive catalogue portfolio of 150,000 products, and many innovative and otherwise unobtainable items, Carbosynth supports the creative requirements of today’s clients.

Carbosynth’s custom synthesis and contract manufacture work for the life science and chemical industries spans over a wide range of chemistries, and supports product development in scales ranging from milligrams to hundreds of kilos.

CONTACT:

Dr. Urs Spitz
Biosynth AG
Phone: +41 79 542 4144
urs.spitz@biosynth.ch
www.biosynth.com

Dr. Vanessa Eastwick-Field
Carbosynth Ltd.
Phone: +44 7887 998 634
vanessa.eastwick-field@carbosynth.com
www.carbosynth.com